1[17]Knight CJ,Panesar M,Wilson DI,et al. Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis[J]. Eur Heart J, 1998,19 (8): 1239-1248
2[18]GarachemaniAR,Kaufmann U,Fleiech M,et al. Prolonged heparin after uncomplicated coronary interventions:a prospective,randomized trial[J]. Am Heart J,1998,136(2):352-356
3[19]Iturbe T,Sanchez C,Moreno JA,et al. Comparative etudy of 2 antithrombotic regiments in 75 patients with coronary endoprostheses[J]. Sangre,1997.42(5) :387-390
4[20]Zidar JP. Low molecular weight heparin in coronary stenting[J]. Can J Cardiol, 1998 ,suppl E: 35E-39E
5[21]Buchwald AB,Hammerschmidt S,Stevens J,et al. Inhibition of neointimal proliferation after coronary angioplasty by low-moleular-weight heparic (clivarine) and polyethyleneglycolhirudin[J]. J Cardiovasc Pharmacol, 1996,28(24):481-487
6[22]Theodore E,Warkentin MD,Mark N ,et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin of unfractionated heparin[J]. N Engl J Med,1995,332(20) :1330-1335
7[23]Lam JYT. Antithrombotic therapy for deep arterial injury by angioplasty.Efficacy of common platelet inhibition compared with thrombin inhibition in pigs [J]. Circulation, 1991,84: 814
8[24]Rigel DF,Olson RW,Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis [J]. Circ Res, 1993,72:1092
9[25]Topol EJ,Bonar R,Jewitc D,et al. Use of a direct antithrombin hirulog in place of heparin during coronary angioplasty[J]. Circulation, 1993,87:1622
10[26]Topol EJ,Bonar R,Jewitc D,et al. Use of a direct antithrombin hirulog in place of heparin during coronary angioplasty[J]. Circulation, 1993,87 :1622
